Buyers have funneled $275 million into a revamped biotech establishing new psoriasis and psoriatic arthritis treatment plans that could be supplied just at the time or two times a calendar year.
The new Oruka Therapeutics released Wednesday as a result of a reverse merger with ARCA biopharma, a Colorado biotech that has undergone various iterations about the last 30 yrs. With the merger, ARCA’s designs are being forged aside in favor of Oruka’s antibody medications, which came from spinout-generator Paragon Therapeutics. Around the final two many years, Paragon has spun out Apogee Therapeutics and Spyre Therapeutics.
Oruka will trade below the Nasdaq ticker “ORKA.”
Continue on to STAT+ to read through the comprehensive story…